CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Brentuximab vedotin|
|Funding Request||For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates|
|Pre Noc Submission||No|
|NOC Date||February 1, 2013|
|Manufacturer||Seattle Genetics, Inc.|
|Sponsor||Seattle Genetics, Inc.|
|Submission Date||March 14, 2013|
|Submission Deemed Complete||March 21, 2013|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||March 28, 2013|
|Check-point meeting||May 8, 2013|
|pERC Meeting||June 20, 2013|
|Initial Recommendation Issued||July 5, 2013|
|Feedback Deadline ‡||July 19, 2013|
|pERC Reconsideration Meeting||August 15, 2013|
|Final Recommendation Issued||August 29, 2013|
|Notification to Implement Issued||September 16, 2013|
|Therapeutic Area||Hodgkin Lymphoma|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.